Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-450/r/ABT-267 + ABT-333 + Ribavirin in Asian Adults with HCV GT1b and Cirrhosis
NCT02517528Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jul 2015
- Primary completion
- Sep 2016
- Modality
- Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 3 trial of ombitasvir, paritaprevir, ritonavir, dasabuvir in hepatitis C (HCV), sponsored by AbbVie Inc.. Started Jul 2015; status: completed.
02
Drugs
ombitasvirparitaprevirritonavirdasabuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02517528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02517528.